Invivyd unveils VMS063 candidate at IDWeek for measles therapy

Invivyd unveils VMS063 candidate at IDWeek for measles therapy
Invivyd presents VMS063 for measles

Invivyd announced the presentation of VMS063, a monoclonal antibody candidate aimed at the treatment and prevention of measles, at IDWeek 2026.

The potential best-in-class candidate demonstrates the companys ongoing efforts to develop advanced therapies targeting infectious diseases.

Invivyd previously announced positive topline results for VYD2311 in a Phase 3 COVID-19 study. The LIBERTY trial showed VYD2311 to be safer and more tolerable than mRNA COVID-19 vaccines. The company has since pursued regulatory submissions for the candidate.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.